Spyre Therapeutics (SYRE) director receives stock options for 8,026 shares at $72.51

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. director Jeffrey W. Albers received a stock option grant covering 8,026 shares of common stock. The option has an exercise price of $72.51 per share and expires on May 27, 2036.

The award vests and becomes fully exercisable upon the earlier of May 27, 2027 or the date of Spyre Therapeutics' 2027 annual meeting of stockholders, as long as Albers continues serving the company through that vesting date. Following this grant, he holds options for 8,026 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Albers Jeffrey W.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,026	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 8,026 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 8,026 shares Exercise price: $72.51 per share Underlying common shares: 8,026 shares +3 more

6 metrics

Option shares granted 8,026 shares Stock Option (Right to Buy) grant on May 27, 2026

Exercise price $72.51 per share Conversion or exercise price of granted option

Underlying common shares 8,026 shares Common stock underlying the option

Total options after grant 8,026 shares Total derivative shares following transaction, held directly

Option expiration May 27, 2036 Expiration date of the stock option

Vesting date trigger Earlier of May 27, 2027 or 2027 annual meeting Condition for full vesting, subject to continuous service

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest and become fully exercisable, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "72.5100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-05-27T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest and become fully exercisable financial

"which will vest and become fully exercisable upon the earlier of May 27, 2027"

continuous service financial

"subject to the Reporting Person's continuous service to the Issuer"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Albers Jeffrey W.

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$72.51	05/27/2026		A		8,026		(1)	05/27/2036	Common Stock	8,026	$0	8,026	D

Explanation of Responses:

1. This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Spyre Therapeutics (SYRE) director Jeffrey W. Albers receive in this Form 4?

Jeffrey W. Albers received a stock option grant for 8,026 shares of Spyre Therapeutics common stock. The option is a compensation-related award and does not reflect an open-market stock purchase or sale, but a right to buy shares in the future if exercised.

What is the exercise price and expiration date of the SYRE stock options granted to Jeffrey W. Albers?

The granted stock option has an exercise price of $72.51 per share and expires on May 27, 2036. This means Albers can choose to buy up to 8,026 shares at $72.51 before that expiration date, once the option is vested and exercisable.

When do Jeffrey W. Albers’ Spyre Therapeutics (SYRE) options vest?

The options vest and become fully exercisable on the earlier of May 27, 2027 or the date of Spyre Therapeutics’ 2027 annual meeting of stockholders. Vesting is contingent on Albers maintaining continuous service to the company through the applicable vesting date.

How many Spyre Therapeutics (SYRE) option shares does Jeffrey W. Albers hold after this transaction?

Following this grant, Albers holds stock options covering 8,026 shares of Spyre Therapeutics common stock directly. These options were acquired as a grant and represent a right to purchase shares in the future, not an immediate ownership of common stock.

Is the Form 4 transaction for SYRE a stock purchase or sale by Jeffrey W. Albers?

The Form 4 reports a grant of stock options to Albers, classified as an acquisition of a derivative security. It is not an open-market stock purchase or sale, but a compensation award giving him the right to buy 8,026 shares at a fixed exercise price if he chooses.